Navigation Links
ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
Date:3/18/2009

o the point of ignoring the cautionary statements contained in the very authority cited by OGD as scientific support for its method, as well as the advice of its own experts.
  • When faced with a safety issue identified in Vancocin's labeling and by its own 2008 advisory committee - the potential for systemic absorption of the drug at toxic levels and the need for pharmacokinetic (PK) testing to address that safety issue - OGD again turned away from patients with CDI. Instead, they concluded that PK testing is unnecessary because the drug is not absorbed in healthy patients who are not infected with CDI.
  • By focusing exclusively on the lower GI tract, the December 2008 Draft Guidance fails to account for another indicated use of Vancocin - Staphylococcus aureus GI infections - which occur in both the upper and lower GI tract.
  • OGD's Q1Q2 sameness standard is flawed and incomplete. OGD acknowledges that inactive ingredients may affect product performance, and that the state of knowledge in this area is underdeveloped. However, OGD proposes without explanation that a Q1Q2 standard developed for oral solutions will nonetheless apply to Vancocin, an oral capsule product. Then, OGD backs off the sameness supposedly ensured by the Q1Q2 standard, and permits generic applicants to vary their inactive ingredients in the absence of any standards to evaluate the effect of such variations on the generic product's performance.

    • "OGD's extensive litany of errors and omissions not only required an equally extensive response, but should cause many to question, as we do, whether OGD has abrogated its decision-making role in bioequivalence method development for Vancocin," continued Doyle.

    While ViroPharma's comments note that numerous flaws prevent use of OGD's proposed new BE method for Vancocin, ViroPharma also believes that, even if the new method was valid, OGD's a
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
    2. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
    3. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
    4. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
    5. ViroPharma Announces Discontinuation of HCV-796 Development
    6. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
    7. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
    8. ViroPharma to Present at the Natixis Bleichroeder Conference
    9. ViroPharma to Present at Three Upcoming Healthcare Conferences
    10. Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
    11. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/23/2013)... CHINA , May 24, 2013 ... or the "Company"), a leading China ... manufacturing and marketing biopharmaceutical products, announced today that, ... "EGM"), the Company,s shareholders voted in favor of ... announced agreement and plan of merger dated February ...
    (Date:5/23/2013)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) ... Life Science Firm of the Year by the Tech Council ... at the TCM,s 25 th Annual Tech Awards Celebration ... Awards Celebration recognizes the leaders and innovators in the technology ... and the surrounding regions. "We are deeply ...
    (Date:5/23/2013)... y PARÍS, 24 de mayo de ... ), un destacado desarrollador y fabricante de herramientas ... la diagnosis y tratamiento de la enfermedad vascular ... del ensayo ADVISE ( Ad enosine V ... E valuation) II durante la sesión de ensayo ...
    Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
    ... Horror stories related to medical equipment for new construction or ... of dollars are wasted, and delays in go-live dates can ... an independent nonprofit that researches the best approaches to improving ... 6 best practices to ensure a better outcome in a ...
    ... Oct. 28 DUSA Pharmaceuticals, Inc.® (Nasdaq GM: ... announced today that global sales volumes of the ... Photodynamic Therapy (PDT) technology platform, surpassed one million ... that dermatologists in the U.S. and abroad continue ...
    Cached Medicine Technology:Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 2Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 3DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units 2
    (Date:5/23/2013)... By Denise Mann HealthDay Reporter , , THURSDAY, ... of Americans take to help treat hip and knee ... increase risk for developing glaucoma, a small new study ... there is an increase of intraocular pressure (IOP) or ... of the leading causes of blindness. ...
    (Date:5/23/2013)... 2013 Memorial Day Focus Spotlight on ... been a part of the U.S. Military for more ... preceding it, these men and women will be honored ... of America. As veterans transition to civilian life, ... the workplace chaplaincy world. , Marketplace Chaplains, America’s ...
    (Date:5/23/2013)... “Talk. They Hear You.” a new national ... talk to children as young as nine years old ... by the Substance Abuse and Mental Health Services Administration ... SAMHSA’s 2013 National Prevention Week—an annual health observance dedicated ... and mental health issues. , SAMHSA’s latest report on ...
    (Date:5/23/2013)... to its destruction inside a cell, a cancer-promoting ... thwart the development of tumor-suppressing microRNAs (miRNAs) before ... publication at Nature . , Under conditions ... epidermal growth factor receptor (EGFR) gums up the ... scientists at The University of Texas MD Anderson ...
    (Date:5/23/2013)... carries a poor prognosis, with limited treatment options. ... the way it,s supposed to. New research from Western ... chemotherapy, and identifies a mechanism to rectify that. ... and his team at Western,s Schulich School of Medicine ... to promote the death of cancer cells by binding ...
    Breaking Medicine News(10 mins):Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3
    ... have arisen about the best approach whether it is public ... that more people want public services offering better health care ... Queen Elizabeth Hospital is an example financial difficulty due to ... study reveals that the health care provided by the not-for-profit ...
    ... a well-known fact that nearly 1/3rd of our lifetime is ... important as the quantity. People who have odd working hours ... chronic sleep deprivation that is responsible for fatigue and other ... North Polar Region have for the first time shed light ...
    ... the University of Washington researchers between obesity and asthma. ... the Journal of Allergy and Clinical Immunology. Previous studies ... develop asthma. The new research reveals the common genetic ... ,The researchers led by Dr. Teal Hallstrand analyzed ...
    ... French are reluctant to place their orders for Christmas turkeys ... ,However, the dreaded disease has not stopped the British and ... year, say industry sources. ,In France, bulk ... orders, say industry sources. The consumer confidence seems to have ...
    ... on bird shows in Britain has been lifted on account of ... ,Various events such as pigeon racing, falconry and other bird shows ... bird flu scare in October which was detected in Eastern Europe ... now since no single case of bird flu was reported the ...
    ... regarding the Christmas dinner. Turkey still remains popular inspite of the ... risen by 25% in Britain. Supermarket owners say that the sales ... ,When bird flu was spreading and was in its peak ... sales will fall very sharply. ,But the health officials ...
    Cached Medicine News:Health News:Reindeer Provide Valuable Insights Into Sleep Disorders 2Health News:Christmas turkey? Anyone? 2
    ... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
    ... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
    ...
    ... Merocel Ophthalmic Products ... superior fiber free products ... and safe cleaning of ... exclusive Merocel material is ...
    Medicine Products: